Bulgarian 
Croatian
Czech 
Danish
Dutch
Estonian
Finnish
French
German
Greek
Hungarian
Icelandic
Italian
Latvian
Lithuanian
Maltese
Norwegian
Polish
Portuguese 
Romanian
Slovak
Slovenian
Spanish
SwedishArticle Contents
A.MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
Name and address of the manufacturer(s) responsible for batch release
Merck Sharp & Dohme BV, Waarderweg 39, 2031 BN Haarlem, The Netherlands or
Laboratories Merck Sharp & Dohme- Chibret, Route de
- Caspofungin accord - caspofungin acetate
Prescription drugs listed. Substance: "Caspofungin"
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
B.CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2)
C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING
- Introna - Merck Sharp
- Vantavo (alendronate sodium and colecalciferol, msd) - Merck Sharp
- Trevaclyn - Merck Sharp
- Neoclarityn - Merck Sharp
- Puregon - Merck Sharp
- Tredaptive - Merck Sharp
Prescription drugs listed. Manufacturer: "Merck Sharp "
AUTHORISATION
Periodic Safety Update Reports
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
- Caspofungin accord - J02AX04
Prescription drugs listed. ATC Code: "J02AX04"
Risk Management Plan (RMP)
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any subsequent updates of the RMP.
An updated RMP should be submitted:
At the request of the European Medicines Agency;
Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
Comments
